secwatch.observer — SEC 8-K summary
======================================

Issuer:     MoonLake Immunotherapeutics (MLTX)
CIK:        0001821586
Form:       8-K
Filed at:   2026-05-11T23:59:59+00:00
Accession:  0001821586-26-000005
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MoonLake aligns with FDA on BLA for sonelokimab in HS; Q1 cash $357.9M
----------------------------------------------------------------------

- FDA pre-BLA meeting positive; alignment on submission plans, adolescent data inclusion, and safety strategy.
- BLA submission planned for end of Sep 2026; Priority Review decision expected within 60 days.
- Proposed label includes ~43% HiSCR75 response and ~29pp delta-to-placebo from MIRA trial, highest in HS.
- Cash $357.9M as of Mar 31, 2026; runway to end of 2027; up to $400M non-dilutive debt facility available.
- R&D expenses $54.5M (stable); G&A $15.5M with $4.8M accelerated stock option cancellation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821586/000182158626000005/0001821586-26-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821586/000182158626000005/mnlk-20260510.htm
  HTML page:      https://secwatch.observer/filing/0001821586-26-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer